Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia. Show more

Location: Level 10, Kuala Lumpur, 592000, Malaysia | Website: https://www.cyclacel.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

14.25M

52 Wk Range

$3.08 - $597.60

Previous Close

$6.77

Open

$6.76

Volume

219,909

Day Range

$6.10 - $6.96

Enterprise Value

9.217M

Cash

4.275M

Avg Qtr Burn

-2.182M

Insider Ownership

79.47%

Institutional Own.

0.80%

Qtr Updated

06/30/25